NCT06580054View on ClinicalTrials.gov

Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 5, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

March 1, 2030

Conditions
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckRecurrent Cutaneous Squamous Cell Carcinoma of the Head and NeckStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
PROCEDURE

Computed Tomography

Undergo CT

OTHER

Digital Photography

Undergo photographs of tumor

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

48109

RECRUITING

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER